CliniGuide

Cover Block

Attribute	Value
Name	CliniGuide
Tagline	Develops digital clinical decision support tools for complex critical care settings like cancer and intensive care.
Headquarters	Montreal, Quebec
Founded	2016
Stage	Seed
Business Model	SaaS
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Funding Label	Seed

Links

• Website: https://cliniguide.ai
• LinkedIn: https://ca.linkedin.com/company/cliniguide-cdss

What an Investor Needs First

CliniGuide is a Montreal-based healthtech startup building digital clinical decision support tools for high-stakes oncology and intensive care workflows. Founded in 2016, the company has developed a SaaS product that consolidates patient data into intelligent dashboards, aiming to surface predictive insights and streamline the preparation for multidisciplinary care meetings [Esplanade Québec]. The core differentiation rests on workflow integration for these specific, complex care settings. Public leadership is anchored by CEO Christophe Vergne, who brings over 25 years of healthcare industry experience to the role [Christophe VERGNE - CliniGuide Inc. | LinkedIn, 2026].

Capitalization is not publicly disclosed. Third-party estimates place revenue around $427,775 with a valuation of approximately $1.4 million, but these figures are unverified [Prospeo]. The company participated in Esplanade Québec's Accélération program for health-impact ventures in 2024 [Esplanade Québec, 2024]. Over the next 12-18 months, key watchpoints are the announcement of a first institutional funding round, the disclosure of initial pilot or customer deployments, and any expansion of the product footprint.

Data Accuracy: YELLOW -- Core product description and CEO background are confirmed; financial and funding data are from a single unverified source.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Funding	Seed

Inside the Company

CliniGuide was founded in 2016 in Montreal, Quebec, with a focus on developing clinical decision support tools for high-acuity medical environments [Esplanade Québec]. The company's public profile centers on its participation in the 2024 cohort of Esplanade Québec's Accélération program [Esplanade Québec, 2024].

Christophe Vergne is identified as the Chief Executive Officer of CliniGuide Inc. [RocketReach]. His LinkedIn profile notes over 25 years of experience in the healthcare industry, with an educational background from IAE Toulouse and Ecole de Management de l'Université Toulouse 1 Capitole [Christophe VERGNE - CliniGuide Inc. | LinkedIn, 2026].

Data Accuracy: YELLOW -- Company description and CEO role confirmed by Esplanade Québec and RocketReach. Founding year and program participation are single-source claims.

Under the Hood

CliniGuide’s product is defined by its focus on high-stakes clinical workflows, specifically in oncology and intensive care. The company develops digital clinical decision support tools that consolidate and analyze patient data into intelligent dashboards, with the stated goal of surfacing critical and predictive information to clinicians [Esplanade Québec]. The design is explicitly for complex, critical care settings where treatment decisions are multidisciplinary and data-heavy.

The core functionality centers on preparing and running multidisciplinary team (MDT) meetings. The product aggregates disparate patient data points into a unified view, aiming to improve the quality and safety of personalized treatment plans [Esplanade Québec]. The company’s website suggests a working, customer-facing application is in use [cliniguide.ai].

Data Accuracy: YELLOW -- Product claims are consistent across the company’s profile and website, but technical specifications, deployment details, and user interface are not publicly visible.

Market Research

The market for clinical decision support systems (CDSS) is expanding beyond general-purpose alerts into specialized, high-stakes environments. The global clinical decision support systems market was valued at $5.9 billion in 2023 and is projected to grow at a compound annual growth rate of 10.2% through 2030 [Grand View Research, 2024].

Demand for solutions like CliniGuide's is anchored in persistent systemic pressures within hospital critical care. Key drivers include the need to reduce clinical variation and medical errors [The Joint Commission]. The push for value-based care models creates financial incentives for tools that improve outcomes. Furthermore, the proliferation of patient data from electronic health records, genomics, and continuous monitoring devices has created an information overload problem [Health Affairs, 2023].

Regulatory and macro forces present both tailwinds and implementation hurdles. In the United States, the 21st Century Cures Act promotes interoperability [U.S. Congress, 2016]. However, software intended to inform clinical diagnosis or treatment decisions may be classified as a SaMD (Software as a Medical Device) and require clearance from bodies like the FDA or Health Canada. In Quebec and Canada, provincial healthcare procurement processes can be lengthy.

Metric	Value
Clinical Decision Support Systems Market (Global)	5.9 $B (2023)
Projected CAGR (2024-2030)	10.2 %
Oncology Information Systems Segment	Multi-$B

Data Accuracy: YELLOW -- Market sizing is based on third-party analyst reports for analogous segments; specific TAM for the company's niche is not confirmed.

Competition and Substitutes

CliniGuide operates at the intersection of two high-stakes, high-complexity healthcare segments where the competitive map is defined by large-scale incumbents, specialized software vendors, and a new wave of AI-native clinical intelligence platforms.

The oncology and intensive care software market is bifurcated. On one side are large-scale electronic health record (EHR) and clinical management suite vendors, such as Epic, Cerner, and McKesson, which offer embedded oncology modules and critical care dashboards [McKesson]. On the other side are specialized, best-of-breed clinical decision support (CDS) and workflow tools. These include oncology-specific platforms like Flatiron Health and Varian's suite, and newer AI-driven CDS companies like Abridge [Abridge, 2025]. CliniGuide's focus on dashboards for multidisciplinary team (MDT) meeting preparation suggests it is competing in this latter, specialized tier.

CliniGuide's potential defensible edge rests on domain-specific workflow design and a Quebec-first distribution path. However, this edge is perishable. Workflow knowledge can be replicated by larger vendors with deeper R&D budgets, and geographic moats are thin if the product lacks deep, proprietary data integrations or regulatory clearances.

Data Accuracy: YELLOW -- Competitive mapping is inferred from the company's described product focus and general market knowledge.

Opportunity

The prize for CliniGuide is a central, reimbursable software layer within the high-stakes, high-cost workflows of oncology and intensive care. The headline opportunity is to become the standard operating system for multidisciplinary tumor boards and critical care rounds in North American hospitals. The shift towards value-based care and bundled payment models in oncology creates financial pressure for hospitals to standardize and optimize treatment pathways [Esplanade Québec, 2024].

Scenario	What happens	Catalyst	Why it's plausible
Provincial Anchor in Quebec	CliniGuide becomes the recommended or procured CDS tool for oncology across the Quebec public health network.	A successful pilot at a major Montreal cancer centre leads to a regional procurement contract.	The company is based in Montreal and participated in a Quebec-focused health accelerator [Esplanade Québec, 2024].
Specialty-Focused Land-and-Expand	The company achieves deep penetration in community oncology clinics.	A partnership with a specialty-focused electronic health record (EHR) vendor.	Oncology is highly specialized, and tools often gain adoption by dominating a specific sub-field.

Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated product focus and participation in a local accelerator.

Sources

1. [Esplanade Québec] CliniGuide Profile | https://esplanade.quebec/portfolio_page/cliniguide/
2. [cliniguide.ai] CliniGuide - Dashboard | https://cliniguide.ai
3. [RocketReach] Christophe Vergne - Chief Executive Officer at CliniGuide Inc. | https://rocketreach.co/christophe-vergne-email_37873672
4. [Christophe VERGNE - CliniGuide Inc. | LinkedIn, 2026] Christophe Vergne Profile | https://ca.linkedin.com/in/christophevergne
5. [Prospeo] CliniGuide revenue and valuation | https://prospeo.io/c/cliniguide-revenue
6. [Esplanade Québec, 2024] 8 entreprises d’impact en santé joignent le programme Accélération | https://esplanade.quebec/8-nouvelles-entreprises-impact-sante-rejoignent-programme-acceleration-sante-2024/
7. [Grand View Research, 2024] Clinical Decision Support Systems Market Size Report | https://www.grandviewresearch.com/industry-analysis/clinical-decision-support-systems-market
8. [The Joint Commission] Sentinel Event Data 2022 Annual Review | https://www.jointcommission.org/resources/patient-safety-topics/sentinel-event/sentinel-event-data/
9. [Health Affairs, 2023] The Promise And Peril Of AI In Clinical Decision Support | https://www.healthaffairs.org/doi/10.1377/hlthaff.2023.00445
10. [U.S. Congress, 2016] 21st Century Cures Act | https://www.congress.gov/114/plaws/publ255/PLAW-114publ255.pdf
11. [McKesson] Oncology Clinical Management Technology | https://www.mckesson.com/specialty/technology-solutions-specialty-practices/oncology-clinical-management-technology/
12. [Abridge, 2025] Bringing Clinical Decision Support Into the Flow of Clinical Conversations | https://www.abridge.com/blog/clinical-decision-support